GLUE ▲ +0.8% - Monte Rosa Therapeutics, Inc.
$GLUE - Monte Rosa Therapeutics Announces Milestone Achievement Associated with Second Phase 2 Clinical Study Initiation for VAV1-directed Molecular Glue Degrader MRT-6160 (DDY391)
28-OCT-2026 07:00 AM ET
Share this post
More filings for $GLUE
GLUE ▼ -6.8% - Monte Rosa Therapeutics, Inc.Oct 2, 2026GLUE ▲ +15.0% - Monte Rosa Therapeutics, Inc.Oct 1, 2026GLUE ▲ +5.8% - Monte Rosa Therapeutics, Inc.Sep 30, 2026GLUE ▲ +1.2% - Monte Rosa Therapeutics, Inc.Sep 8, 2026GLUE ▼ -0.5% - Monte Rosa Therapeutics, Inc.Sep 2, 2026GLUE ▼ -0.2% - Monte Rosa Therapeutics, Inc.Sep 1, 2026
View full $GLUE filing history →💬 Comments
Loading comments…
Leave a comment